Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT) by M. Karolyi, E. Pawelka, S. Omid, F. Koenig, V. Kauer, B. Rumpf, W. Hoepler, A. Kuran, H. Laferl, T. Seitz, M. Traugott, V. Rathkolb, M. Mueller, A. Abrahamowicz, C. Schoergenhofer, M. Hecking, A. Assinger, C. Wenisch, M. Zeitlinger, B. Jilma, A. Zoufaly, A. Zoufaly

Get full text